Zinc Finger Proteins Modulate Neurotrophic Factors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neuropathies such as diabetic neuropathy, neuropathic pain, and neurodegenerative conditions like Parkinson's disease are limited, with neurotrophic factors like NT-3 and GDNF facing challenges due to short half-life, poor bioavailability, and toxicities associated with recombinant protein use and gene transfer.
Innovation Solution
Engineered zinc finger proteins (ZFPs) are designed to modulate the expression of NT-3 and GDNF by binding to specific target sites, allowing for the regulation of these neurotrophic factors to treat neuropathies through fusion proteins and nucleic acid compositions delivered via viral or non-viral vectors, including stem cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If recombinant NT-3 protein is used for treatment, then neural regeneration is promoted, but the therapy is limited by short half-life and poor bioavailability
Solution Approach 1:
The patent introduces a nucleic acid composition that encodes zinc finger proteins capable of binding to regulatory sequences of neurotrophic factor genes (NT-3, GDNF, BDNF, VEGF). This preliminary genetic setup allows the body to produce the therapeutic proteins endogenously, eliminating the need for repeated administration of recombinant proteins and thereby extending the effective duration of action.
2Reliability
If high doses of recombinant neurotrophic proteins are administered, then therapeutic effect is enhanced, but dose-limiting toxicities occur
Solution Approach 1:
The patent employs endogenous gene expression systems where zinc finger proteins bind to regulatory sequences and modulate the production of neurotrophic factors within the patient's own cells. This self-service approach allows physiological regulation of protein levels, avoiding the toxicities associated with high-dose exogenous recombinant protein administration while maintaining therapeutic efficacy.
3Reliability
If gene transfer of NT-3 cDNA is performed, then preclinical efficacy against neuropathy is achieved, but over-production of NT-3 protein results in unwanted toxicities
Solution Approach 1:
The patent utilizes zinc finger proteins that bind to specific regulatory sequences in the promoter regions of neurotrophic factor genes. This binding provides a feedback mechanism that regulates gene expression levels, preventing over-production of therapeutic proteins while maintaining sufficient levels for efficacy, thereby avoiding the toxicities associated with uncontrolled over-expression.
4Reliability
If traditional recombinant protein therapies are used, then treatment of neuropathies is achieved, but the approach lacks physiological regulation and safety
Solution Approach 1:
The patent replaces the mechanical administration of recombinant proteins (injections, infusions) with a biological system based on endogenous gene expression. Zinc finger proteins bind to regulatory DNA sequences to modulate transcription of neurotrophic factor genes, creating a self-regulating physiological system that automatically adjusts protein production based on cellular needs, thereby achieving both simplicity and physiological regulation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The engineered ZFPs effectively upregulate NT-3 and GDNF expression, promoting neural regeneration and reducing neuropathic pain, as demonstrated in various animal models, offering a safer and more physiological approach compared to traditional recombinant protein therapies.
Implementation Method 1
Engineered zinc finger proteins (ZFPs) are designed to modulate the expression of NT-3 and GDNF by binding to specific target sites
Data Source
Figure 1A~1C
Figure 2A
Figure 2B
AI summary
Disclosed herein are methods and compositions for treating neuropathies by modulating endogenous NT-3 of GDNF gene expression.